Home Pharmaceutical asia-pacific-car-t-cell-therapy-treatment-market

Pharmaceutical

Image

Asia-Pacific CAR-T Cell Therapy Treatment Market - Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Published Report
  • May 2021
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 165
  • No of Figures: 52

Asia-Pacific CAR-T Cell Therapy Treatment, By Product (Autologous CAR-T Cells, Allogeneic CAR-T Cells), Structure (First Generation CAR-T Cells, Second Generation Car-T Cells, Third Generation CAR-T Cells, Fourth Generation CAR-T Cells), Targeted Antigens (Antigens on Solid Tumors, Antigens on Hematologic Malignancies, Others), Brand (Yescarta, Kymriah, Tecartus, Others), Therapeutic Application (Hematological Malignancies, Pancreatic Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Multiple Myeloma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Acute Lymphoblastic Leukemia, Others), End User (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospitals Pharmacy, Others), Country (Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends and Forecast to 2028

Asia-Pacific CAR-T Cell Therapy Treatment Market

Market Analysis and Insights: Asia-Pacific CAR-T Cell Therapy Treatment Market

Asia-Pacific CAR-T cell therapy treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 30.8% in the forecast period of 2021 to 2028 and is expected to reach USD 267.08 million by 2028. Increase in usage of CAR-T cell therapy for the treatment of cancer and infectious diseases and increasing prevalence of cancer are the major drivers which propelled the demand of the market in the forecast period.

CAR-T cell therapy treatment comprises features such increasing need for safe and effective product will impact in launching new product by the manufactures into the market which enhance its demand as well as increasing investment in research and development leads to the market growth. Rising investment in research regarding the development of CAR-T cell therapy is expected to provide various other opportunities in the CAR-T cell therapy treatment market. However, adverse side effects of therapies and high cost associated with therapies expected to restraint the market growth in the forecast period.

The demand for the CAR-T cell therapy treatment has been increased in both developed as well as in developing countries and the reason behind this is a rise in awareness about immunotherapies for the CAR-T cell therapy treatment and increase in investment for research and development. The CAR-T cell therapy treatment market will grow in the forecasted period with the increasing prevalence of cancers.

The adverse side effects of therapies and high cost associated with therapies are expected to restraint the CAR-T cell therapy treatment market growth.

The CAR-T cell therapy treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

Asia-Pacific CAR-T Cell Therapy Treatment Market

Asia-Pacific CAR-T Cell Therapy Treatment Market Scope and Market Size

CAR-T cell therapy treatment market is segmented on the based on the basis of product, structure, targeted antigens, brand, therapeutic application, end user, distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of product, the CAR-T cell therapy treatment market is segmented into autologous CAR-T cells and allogeneic CAR-T cells. In 2021, autologous CAR-T cells segment is expected to dominate the CAR-T cell therapy treatment market because the drugs approved for CAR-T cell therapy are autologous in nature. These cells are easy to manufacture because they are derived from the patient own cells or plasma. Moreover, intensive research is ongoing on autologous cells.
  • On the basis of structure, the CAR-T cell therapy treatment market is segmented into first generation CAR-T cells, second generation CAR-T cells, third generation CAR-T cells and fourth generation CAR-T cells. In 2021, second generation CAR-T cells segment is expected to dominate the CAR-T cell therapy treatment market because the approved therapies are second generation based structure. Moreover, second generation are highly specific in nature which recognizes and binds tumor specific antigens.
  • On the basis of targeted antigens, the CAR-T cell therapy treatment market is segmented into antigens on solid tumors, antigens on hematologic malignancies and others. In 2021, antigens on hematologic malignancies segment is expected to dominate the CAR-T cell therapy treatment market because drugs approved for CAR-T cell therapy are majorly used for hematologic malignancies and ongoing extensive research development.
  • On the basis of brand, the CAR-T cell therapy treatment market is segmented into yescarta, kymriah, tecartus and others. In 2021, yescarta segment is expected to dominate the CAR-T cell therapy treatment market because yescarta is the first approved CAR-T cell therapy for oncology therapeutic class. Moreover, yescarta accounts the highest sale.
  • On the basis of therapeutic application, the CAR-T cell therapy treatment market is segmented into hematological malignancies, pancreatic cancer, breast cancer, lung cancer, gastric cancer, multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, acute lymphoblastic leukemia and others. In 2021, hematological malignancies segment is expected to dominate the CAR-T cell therapy treatment market because yescarta accounts the major revenue in the market and the follicular lymphoma is the major indication for yescarta.
  • On the basis of end user, the CAR-T cell therapy treatment market is segmented into hospitals, specialty clinics and others. In 2021, hospitals segment is dominating the CAR-T cell therapy treatment market because CAR-T cell therapy required highly trained professionals with advanced technology laboratories. So, the hospitals have all the advanced equipment and technology with trained professionals.
  • On the basis of distribution channel, the CAR-T cell therapy treatment market is segmented into hospitals pharmacy and others. In 2021, hospitals pharmacy segment is expected to dominate the CAR-T cell therapy treatment distribution channel because hospitals pharmacy are the central part of the hospitals, all the infusion related and medication related delivery sold by the pharmacy department.

CAR-T Cell Therapy Treatment Market Country Level Analysis

The CAR-T cell therapy treatment market is analyzed and market size information is provided on the basis of product, structure, targeted antigens, brand, therapeutic application, end user, distribution channel as referenced above.

The countries covered in the CAR-T cell therapy treatment market report are the Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, and Rest of Asia-Pacific.

Autologous CAR-T cells segment in Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 due to continuous research and development related to the CAR-T cell therapy. Japan is leading the growth of the Asia-Pacific market and autologous CAR-T cells segment is dominating in this country because due to increasing healthcare expenditure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Rise in Awareness about Immunotherapies and Increasing Investment in Research and Development are Boosting the Market Growth of CAR-T Cell Therapy Treatment Market

CAR-T cell therapy treatment market also provides you with detailed market analysis for every country growth in CAR-T cell therapy treatment industry with CAR-T cell therapy treatment drugs sales, impact of advancement in the CAR-T cell therapy treatment technology and changes in regulatory scenarios with their support for the CAR-T cell therapy treatment market. The data is available for historic period 2010 to 2019.

Competitive Landscape and CAR-T Cell Therapy Treatment Market Share Analysis

CAR-T cell therapy treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to CAR-T cell therapy treatment market.

The major companies which are dealing in the CAR-T cell therapy treatment are Autolus, Amgen Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., AbbVie Inc., Novartis AG, Cartherics Pty ltd, CARINA BIOTECH, and TC BIOPHAR Mamong others global and domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the CAR-T cell therapy treatment market.

For instance,

  • In February 2021, AbbVie Inc. had announced the collaboration with the Caribou Biosciences which is the biotechnology leading company in the clinical-stage CRISPR genome editing. The companies have entered into the collaboration and license agreement for the research and development of the chimeric antigen receptor (CAR)-T cell therapeutics. The allogeneic CAR-T cell therapies showed positive impact on the cancer patients but the rejection of CAR-T cells by the host immune system has been considered as one of the challenge for the researchers therefore, Caribou Biosciences technology that is CRISPR genome editing will be engineered to the CAR-T cells so that it can endure the host immune attack which can benefit the large patient population. This collaboration helped the company to be considered in the market who is involved in the development of the innovative CAR-T therapies and overcome the issues related with this therapy which will increase the status in the market and directly increases their company growth.
  • In July 2020, Kite Pharma (a subsidiary of Gilead Sciences, Inc.) had announced that the company has received the USFDA approval for Tecartus (brexucabtagene autoleucel) which was previously known as KTE-X19 which was considered as only CAR-T cell therapy for the treatment of refractory mantle cell lymphoma (MCL). The product has been granted with Breakthrough Therapy Designation (BTD) from FDA. The single infusion of this product found 62% had showed complete response and 87% patients’ responded positive. This product is considered as the first cell therapy for the patients suffering from relapsed/refractory MCL. This helped the company to get recognized as one of the company to develop a CAR-T cell therapy for the treatment of the refractory large B-cell lymphoma after the two or three therapies which will increase the demand in the market.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the CAR-T cell therapy treatment market which also provides the benefit for organization to improve their offering for CAR-T cell therapy.

SKU-

TABLE 1 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 BELOW PROVIDED ARE THE ALTERNATIVE CHEMOTHERAPIES OF CAR-T CELL THERAPY:

TABLE 3 TOTAL HEALTH SPENDING BY THE U.S. (2015-2016)

TABLE 4 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET, BY MOLECULE, 2019-2028 (USD MILLION)

TABLE 5 ASIA-PACIFIC AUTOLOGOUS CAR-T CELLS IN CAR-T CELL THERAPY TREATMENTMARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 6 ASIA-PACIFIC ALLOGENEIC CAR-T CELLS IN CAR-T CELL THERAPY TREATMENTMARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET, BY STRUCTURE, 2019-2028 (USD MILLION)

CELYAD IS ENGAGED IN THE MANUFACTURING OF CYAD-211, A FIRST GENERATION CAR-T CELL THERAPY EXPRESSING BCMA TARGETING CHIMERIC ANTIGEN RECEPTOR WHICH INTERFERES WITH THE EXPRESSION OF THE CD3Ζ OF T CELL RECEPTOR COMPLEX. 

TABLE 8 ASIA-PACIFIC FIRST GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 ASIA-PACIFIC SECOND GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 ASIA-PACIFIC THIRD GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 ASIA-PACIFIC THIRD GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 12 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 13 ASIA-PACIFIC ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 14 ASIA-PACIFIC ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY ANTIGENS ON HEMATOLOGIC MALIGNANCIES, 2019-2028 (USD MILLION)

TABLE 15 ASIA-PACIFIC ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENTMARKET , BY REGION, 2017-2028 (USD MILLION)

TABLE 16 ASIA-PACIFIC ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY ANTIGENS ON SOLID TUMORS, 2019-2028 (USD MILLION)

TABLE 17 ASIA-PACIFIC OTHERS IN CAR-T CELL THERAPY TREATMENTMARKET , BY REGION, 2017-2028 (USD MILLION)

TABLE 18 ASIA-PACIFIC YESCARTA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 19 ASIA-PACIFIC YESCARTA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 20 ASIA-PACIFIC KYMRIAH IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 21 ASIA-PACIFIC TECARTUS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 22 ASIA-PACIFIC OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 23 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)

TABLE 24 ASIA-PACIFIC FOLLICULAR LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2017-2028 (USD MILLION)

TABLE 25 ASIA-PACIFIC DIFFUSE LARGE B-CELL LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 26 ASIA-PACIFIC ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 27 ASIA-PACIFIC MANTLE CELL LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 28 ASIA-PACIFIC MULTIPLE MYELOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 29 ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 30 ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 31 ASIA-PACIFIC LUNG CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 32 ASIA-PACIFIC CHRONIC LYMPHOCYTIC LEUKEMIA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 33 ASIA-PACIFIC GASTRIC CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 34 ASIA-PACIFIC PANCREATIC CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 35 ASIA-PACIFIC BREAST CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 36 ASIA-PACIFIC OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 37 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 38 ASIA-PACIFIC HOSPITALS IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2017-2028 (USD MILLION)

TABLE 39 ASIA-PACIFIC SPECIALTY CLINICS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 40 ASIA-PACIFIC OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 41 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 42 ASIA-PACIFIC HOSPITAL PHARMACY IN CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2028 (USD MILLION)

TABLE 43 ASIA-PACIFIC OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 44 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 46 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)

TABLE 47 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 48 ASIA-PACIFIC ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 49 ASIA-PACIFIC ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 50 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)

TABLE 51 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 52 ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 53 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 54 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 55 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 56 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)

TABLE 57 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 58 JAPAN ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 59 JAPAN ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 60 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)

TABLE 61 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 62 JAPAN HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 63 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 64 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 65 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 66 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)

TABLE 67 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 68 AUSTRALIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 69 AUSTRALIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 70 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)

TABLE 71 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 72 AUSTRALIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 73 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 74 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 75 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 76 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)

TABLE 77 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 78 SINGAPORE ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 79 SINGAPORE ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 80 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)

TABLE 81 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 82 SINGAPORE HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 83 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 84 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 85 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 86 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)

TABLE 87 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 88 CHINA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 89 CHINA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 90 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)

TABLE 91 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 92 CHINA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 93 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 94 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 95 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 96 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)

TABLE 97 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 98 SOUTH KOREA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 99 SOUTH KOREA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 100 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)

TABLE 101 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 102 SOUTH KOREA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 103 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 104 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 105 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 106 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)

TABLE 107 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 108 INDIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 109 INDIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 110 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)

TABLE 111 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 112 INDIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 113 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 114 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 115 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 116 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)

TABLE 117 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 118 MALAYSIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 119 MALAYSIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 120 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)

TABLE 121 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 122 MALAYSIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 123 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 124 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 125 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 126 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)

TABLE 127 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 128 THAILAND ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 129 THAILAND ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 130 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)

TABLE 131 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 132 THAILAND HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 133 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 134 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 135 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 136 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)

TABLE 137 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 138 INDONESIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 139 INDONESIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 140 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)

TABLE 141 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 142 INDONESIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 143 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 144 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 145 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 146 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)

TABLE 147 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 148 PHILIPPINES ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 149 PHILIPPINES ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 150 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)

TABLE 151 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 152 PHILIPPINES HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 153 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 154 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 155 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 156 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)

TABLE 157 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 158 VIETNAM ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 159 VIETNAM ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 160 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)

TABLE 161 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 162 VIETNAM HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 163 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 164 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 165 REST OF ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

BROWSE RELATED REPORTS

Global CAR-T Cell Therapy treatment Market – Industry Trends and Forecast to 2030
MEA CAR-T Cell Therapy Treatment Market – Industry Trends and Forecast to 2031
Europe CAR-T Cell Therapy Treatment Market – Industry Trends and Forecast to 2028
North America CAR-T Cell Therapy Treatment Market - Industry Trends and Forecast to 2028

BROWSE RELATED Blogs

Global CAR-T Cell Therapy Treatment Market is Growing with 30.0% in the Forecast Period of 2021 to 2028

BROWSE RELATED Press Release

50.08% of Global CAR-T Cell Therapy Treatment Market Revenue is generated by Yescarta Segment
The Increasing Prevalence of Cancer and Other Targeted Diseases is Expected to Drive the Growth of MEA, Saudi Arabia and SEA CAR-T Cell Therapy Treatment Market
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Can be used by entire organization across the globe + Downloadable and Printable PDF + 30 + Countries

Buy Now
Request for TOC Speak to Analyst Inquire Before Buying Free Sample Report
Advance Formative Research Customization Request for bulk Reports

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials

David Manning - Thermo Fisher Scientific
Director, Global Strategic Accounts,

Dear Ricky,
I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.

Image
Manager - Market Analytics,
Uriah D. Avila - Zeus Polymer Solutions

Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.

Business Development Manager,
(Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC

DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.

Image
Business Intelligence and Analytics,
Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Image
Competition Analyst,
Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Image
Marketing Director,
Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

COO,
A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Image
Marketing Director,
Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Image
Product manager,
Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Image
Investor relations,
GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Image
Market Analyst,
Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Image
Andrew - Senior Global Marketing Manager,
Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Image
Amarildo - Manager, Global Strategic Alignment
MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Image
Tor Hammer
Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Tommaso Finocchiaro
Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Yuki Kopyl (Asian Business Development Department)
UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future